Product Description
Pethidine is commonly used in single doses as a preoperative medication or in multiple doses as an analgesic. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/359212/)
Mechanisms of Action: OPRM Agonist, OPRK Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Czech | Dominican Republic | Egypt | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Malaysia | Malta | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Saudi Arabia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Jinan Bainuo Pharmaceutical Technology Development Co., Ltd.
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Myocardial Infarction|Pain Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20132554 |
CTR20132554 | P3 |
Active, not recruiting |
Pain Unspecified |
2013-11-12 |
2025-04-29 |
Patient Enrollment|Treatments |
|
2016-004501-14 |
COOL AMI EU PIVOTAL TRIAL | P3 |
Active, not recruiting |
Myocardial Infarction |
None |
2025-07-05 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|